Last reviewed · How we verify
NCT06338839: TETRAMER
Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia
trial in Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction in 1,770 participants. Terminated before completion.
25 June 2024
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 1,770 |
| Start date | 28 December 2023 |
| Primary completion | 25 June 2024 |
| Estimated completion | 25 June 2024 |
| Sites | 21 locations across Russia |
Conditions studied
- Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction — all drugs for Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, any sex, with Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multicenter observational retrospective-prospective study of prevalence and clinical characteristics of transthyretin amyloidosis (ATTR) cardiomyopathy (CM) in Russian patients with heart failure with preserved ejection fraction (HFpEF) in real clinical practice. The retrospective phase will entail secondary data collection from electronic or paper medical records of patients who are participating/participated in the PRIORITY-CHF study and have HFpEF. Those patients who have a high suspicion of having ATTR-CM and provided informed consent will be invited to participate in the prospective phase. The prospective phase will consist of three visits, during which a routine comprehensive cardiologic evaluation in order to confirm or exclude ATTR-CM diagnosis will be performed. In patients with confirmed ATTR-CM the material for genetic testing will be collected in order to specify the type of ATTR-amyloidosis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06338839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06338839 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06338839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing